Legal & General Group Plc Acquires New Stake in Inspire Medical Systems, Inc. $INSP

Key Points

• Legal & General Group acquired 61,236 shares of Inspire Medical Systems worth approximately $2.7 million, while institutional investors overall own 94.91% of the company.
• Inspire reported quarterly adjusted earnings of $0.14 per share and revenue of $200.58 million, beating analyst expectations, though revenue declined 7.6% year over year.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $66.19; the stock recently opened at $62.99.

Legal & General Group Plc bought a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 61,236 shares of the company's stock, valued at approximately $2,732,000. Legal & General Group Plc owned approximately 0.21% of Inspire Medical Systems as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Alberta Investment Management Corp bought a new stake in Inspire Medical Systems during the second quarter valued at approximately $5,483,000. GSA Capital Partners LLP bought a new position in shares of Inspire Medical Systems in the 2nd quarter worth $820,000. Bank of Nova Scotia raised its position in shares of Inspire Medical Systems by 49.8% during the 1st quarter. Bank of Nova Scotia now owns 60,000 shares of the company's stock valued at $3,095,000 after buying an additional 19,958 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Inspire Medical Systems by 66.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company's stock valued at $38,561,000 after buying an additional 344,221 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Inspire Medical Systems during the 1st quarter worth $1,799,000. Hedge funds and other institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Price Performance

INSP opened at $62.99 on Friday. The stock's 50 day simple moving average is $55.05 and its 200 day simple moving average is $52.43. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of 13.63, a PEG ratio of 4.79 and a beta of 0.70. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The firm had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. During the same quarter in the prior year, the firm posted $0.45 earnings per share. The business's quarterly revenue was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, sell-side analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on INSP. KeyCorp reissued a "sector weight" rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Stifel Nicolaus set a $75.00 price objective on Inspire Medical Systems in a report on Tuesday, August 4th. Royal Bank Of Canada reissued a "sector perform" rating and set a $60.00 price objective on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Zacks Research raised Inspire Medical Systems from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 17th. Finally, UBS Group assumed coverage on shares of Inspire Medical Systems in a research report on Tuesday, July 28th. They set a "sell" rating and a $39.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inspire Medical Systems currently has a consensus rating of "Hold" and an average price target of $66.19.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the firm's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider owned 18,985 shares of the company's stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is currently owned by company insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.